News
KA
2.320
-7.94%
-0.200
Weekly Report: what happened at KA last week (0219-0223)?
Weekly Report · 1d ago
Kineta To Present New Preclinical Data On Its Anti-VISTA Antibody KVA12123 In Acute Myeloid Leukemia At The AACR Blood Cancer Discovery Symposium
Kineta will present new preclinical data on KVA12123, the Company's anti-VISTA antibody, in acute myeloid leukemia. Kineta is a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology. The company will present at the American Association for Cancer Research.
Benzinga · 5d ago
Weekly Report: what happened at KA last week (0212-0216)?
Weekly Report · 02/19 12:43
Weekly Report: what happened at KA last week (0205-0209)?
Weekly Report · 02/12 12:27
Weekly Report: what happened at KA last week (0129-0202)?
Weekly Report · 02/05 12:41
Weekly Report: what happened at KA last week (0122-0126)?
Weekly Report · 01/29 12:22
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Kineta (KA), Gilead Sciences (GILD) and Evotec AG (EVO)
TipRanks · 01/23 09:50
Analysts Offer Insights on Healthcare Companies: Kineta (KA), Eli Lilly & Co (LLY) and Iovance Biotherapeutics (IOVA)
TipRanks · 01/23 08:31
Weekly Report: what happened at KA last week (0115-0119)?
Weekly Report · 01/22 12:29
HC Wainwright & Co. Reiterates Buy on Kineta, Maintains $8 Price Target
Benzinga · 01/18 11:40
KINETA INC: Current report
Press release · 01/17 16:08
Kineta Provides Update On Its Ongoing Phase 1/2 VISTA-101 Clinical Trial Of KVA12123 In Patients With Advanced Solid Tumors
Cleared First Four Monotherapy Doses and Initial Combination Cohort with No Dose Limiting Toxicities at any Dose Level KVA12123 Monotherapy Demonstrated Dose Proportional Induction of Pro-inflammatory Biomarkers required for strong anti-tumor activity. Kineta's novel VISTA blocking immunotherapy, cleared the first four monotherapy dose levels in the VISTA-101 Phase 1/2 clinical trial. Additional Monotherapy Clinical Efficacy Data expected in Q2 2024.
Benzinga · 01/17 13:31
Weekly Report: what happened at KA last week (0108-0112)?
Weekly Report · 01/15 12:23
Weekly Report: what happened at KA last week (0101-0105)?
Weekly Report · 01/08 12:29
KINETA INC: Current report
Press release · 01/05 23:28
Weekly Report: what happened at KA last week (1225-1229)?
Weekly Report · 01/01 12:21
Weekly Report: what happened at KA last week (1218-1222)?
Weekly Report · 12/25/2023 12:39
Weekly Report: what happened at KA last week (1211-1215)?
Weekly Report · 12/18/2023 12:49
KINETA INC: Current report
Press release · 12/15/2023 15:11
More
Webull provides a variety of real-time KA stock news. You can receive the latest news about KINETA INC through multiple platforms. This information may help you make smarter investment decisions.
About KA
Kineta, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing differentiated immunotherapies that address the challenges with current cancer therapy. Its innate immunity development platform aimed at developing human antibodies to address the mechanisms of cancer immune resistance, such as immuno-suppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of assets and research interests includes KVA12123, a monoclonal antibody (mAb), immunotherapy targeting V-domain Ig suppressor of T cell activation (VISTA), an anti-CD27 agonist mAb immunotherapy and an anti-CD24 antagonist mAb immunotherapy discovery program. VISTA blocks immunotherapy to address the problem of immunosuppression in the tumor microenvironment. It is developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells in the tumor microenvironment. KVA12123 are primarily focused on solid tumors with high levels of VISTA expression.